Diabetic Foot Ulcer Clinical Trial
Official title:
Treatment of Diabetic Foot Ulcers With Inforatio Technique to Promote Wound Healing: a Feasibility Trial
This trial will examine the feasibility of conducting a definitive randomized clinical trial
that tests whether inforatio technique will reduce time to healing of diabetic foot ulcers.
Inforatio technique is a procedure where small punch biopsies are taken from the wound bed
near the edge of the wound. With this technique, the investigators wish to initiate an acute
inflammatory response that increases the generation of granulation tissue with subsequent
healing by scar formation. Thus, the investigators hypothesize that inforatio technique will
promote healing of diabetic foot ulcers.
Based on clinical experience, the investigators have previously detected a reduction in time
to healing as an unexpected effect when multiple punch biopsies are taken from the wound bed
of diabetic foot ulcers. To the knowledge of the investigators, methods similar to the
inforatio technique has not previously been studied.
BACKGROUND
The prevalence of diabetic foot ulcers is expected to increase considerably due to a
continuously increasing prevalence of diabetes. The healing process of diabetic foot ulcers
is complicated by a complex pathophysiology of the distal lower extremities and a constant
exposure to bacteria and pressure. Improving healing of diabetic foot ulcers will have
several benefits including higher quality of life, reduced morbidity, reduced mortality and
lower socioeconomic costs. Nonetheless, there are few randomized controlled clinical trials
on surgical and non-surgical treatment chronic foot ulcers and many studies on the topic have
a low level of evidence.
TRIAL AIMS
The investigators aim to assess the feasibility of conducting a definitive randomized
controlled trial by exploring recruitment, patient acceptability, protocol adherence and
adverse effects.
The success criteria of the trial is as follows:
- Weekly recruitment rates at two patients or more.
- Time from first outpatient visit to recruitment at 21 days or less.
- Retention rate at 90-day follow-up at 50% or more
- No appearance of unacceptable adverse effects In addition, the trial aims to assess
logistic concerns regarding the trial and to improve the method of inforatio
application.
Based on findings from the feasibility trial, the investigators may amend the design of the
definitive trial.
RECRUITMENT
Patients are eligibility-screened and identified by the primary investigator and wound care
staff when patients visit wound outpatient clinics at the recruiting facilities.
INCLUSION AND FOLLOW-UP
Eligible patients are included if they give their oral and written consent to participate.
The baseline trial visit take place on the day that patients give their consent to
participate.
The trial comprises a 90-day clinical follow-up. Follow-up visits will be at 10, 21, 42 and
90 days after baseline (give or take 3 days). Wounds are assessed at each trial visit. The
inforatio technique is applied at baseline and again at the 21-follow-up day if the wound
still has a diameter larger than four mms. Participants unable to attend at the precise dates
for midtrial follow-up will be eligible for follow-up three days before or after the intended
date. The participants who cannot attend during this window will skip the follow-up day in
concern. If the participants miss the second intervention at the 21-day follow-up, they are
excluded. For the 90-day follow-up, participants are recalled two times by the primary
investigator within two weeks before being excluded.
Participants exit from the trial if following occurs during follow-up:
- they undergo surgeries described in the exclusion criteria
- they get acute signs of infection, gangrene or osteomyelitis in their foot in concern
- their tendons, joints or bone become exposed in the wound bed
- they develop an acute phase of charcot arthropathy in their foot in concern
- they get admitted for reasons related to their foot ulcer
- they die or emigrate
The trial is stopped if the intervention shows an unintended effect or potential harm.
TRIAL STANDARD TREATMENT
The participants receive a trial standard treatment at every trial visit. The treatment is
conducted by the primary investigator in cooperation with wound care nurses and podiatrists.
The standard treatment is defined based on Danish National guidelines, local guidelines of
the recruiting facilities and guidelines of the National Institute for Health and Care
Excellence.
The treatment is based on a flowchart that individualizes treatment based on clinical wound
characteristics.
INFORATIO TECHNIQUE
The technique is described in the Arms and Interventions section.
TRIAL MEASURES
Wound assessment: Wounds are assessed at every trial visit. To monitor the ulcer area during
follow-up, the investigators will analyze digital photos of the ulcer by using Image J which
is a wound planimetry software. The depth of the ulcers are measured with sterile wound
probes and reported by intervals of 5 millimeters. Undermining will be assessed with the same
method as for depth and in intervals of 5 millimeters.
Microbial samples: At both stages of inforatio application, three punch biopsies are sent for
cultivation to analyze bacterial species, bacterial load and resistance patterns of the
bacteria.
Patient and staff interviews: described in the Outcome Measures section
STATISTICAL ANALYSIS
With descriptive statistics participants' demographics, the quantitative success criteria,
the quantitative outcome measures and time to healing will be reported. Clinical healing is
defined by intact epithelia.
The investigators will use statistical software SPSS version 21.0 (IBM Corp., Armonk, New
York).
SAMPLE SIZE CONSIDERATION
Because effectiveness is not evaluated, a formal power calculation is not considered
necessary for the objectives of a feasibility trial.
To minimize the number of patients that are exposed to a new intervention meanwhile keeping a
level of precision for the variance estimate, the rule of thumb by Julious et al will be used
for determination of the trial sample size. Thus, 12 participants will be included in the
trial. Julious et al argues that a sample size of 12 per group gives a sufficient precision
of the mean and variance estimates. Other studies report rules of thumbs with larger sample
size to gain sufficient power for a pilot or feasibility trial.
ETHICAL CONSIDERATIONS AND RISK ASSESSMENT OF SIDE EFFECTS
The procedure of the intervention is small with an expectedly small risk of harm outcomes.
The punch biopsies from the inforatio technique is relatively shallow therefore it is not
expected that it will penetrate important anatomical structures or expose bone.
The primary investigator's clinical assessment, patient preference and patient tolerance is
taken into consideration before inforatio technique is applied. Minimal discomfort is
expected for the participants when they receive the inforatio technique treatment. Previous
applications by the investigators showed that patients reported no or little pain during
application.
The inforatio technique treatment has previously shown potential to improve healing thus
participants may gain an improvement in healing of their foot ulcers.
If this trial shows that a definitive randomised clinical trial will be feasible, the
investigators will examine the effect of inforatio technique through a larger randomised
clinical trial. If the inforatio technique shows significant positive effect on time to
healing it would become of great importance for future diabetic foot ulcer patients. The
inforatio technique would become an addition to available therapeutic options. The technique
is simple and only requires a punch biopsy tool. Nurses and general practitioners can be
potential applicants that apply the treatment at clinics close to patient habitats making
visits for wound treatment more convenient for the patients. If there is a significant
positive effect on healing, it is expected that it will result in reduction of hospital
admissions and less surgical interventions including amputations.
This project may contribute to more focus on treatment of patients with diabetic foot ulcers
- a field of research that still needs studies to enable evidence-based treatment.
Inspectors from The National Committee of Health Research Ethics will have the authorization
to quality control the trial.
COMPETING INTERESTS
The trial investigators declare that they have no competing interests.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauzeā¢ Alone and Regranex®Gel 0.01% Plus TheraGauzeā¢ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |